The brand product, Pfizer's Depo-Medrol injection, has annual sales of approximately $41.4 million.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced today that the US Food and Drug Administration has granted final approval for the company's ANDA for methylprednisolone acetate injectable suspension, 40 mg/mL and 80 mg/mL in single dose vials.
Teva's methylprednisolone acetate injectable suspension is the AP-rated generic equivalent of Pfizer's Depo-Medrol injection, an anti-inflammatory glucocorticoid for intramuscular, intrasynovial, soft tissue or intralesional injection.
The brand product has annual sales of approximately $41.4 million.